All
Combination Approved for BRAF-Positive Lung Cancer
June 23rd 2017The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) gained approval from the Food and Drug Administration (FDA) for the treatment of patients with BRAF V600–positive advanced or metastatic non–small cell lung cancer (NSCLC).
FDA Approves Rituxan Hycela for Blood Cancers
June 22nd 2017Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Using an App to Reduce Cancer-Related Anxiety
June 21st 2017Joseph Greer, Ph.D., Clinical Director of Psychology and Research Scientist in the Center for Psychiatric Oncology & Behavioral Sciences at Massachusetts General Hospital, explains a mobile app to help anxiety in patients who have incurable cancer.